COMMUNIQUÉS West-GlobeNewswire

Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
15/09/2025
Partnership strengthens Nugevia ™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) [...]
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
15/09/2025
BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Excision BioTherapeutics Announces Positive Preclinical Data Highlighting the Safety, Potency and Development Progress of the Hepatitis B EBT-107 Program at the ICE-HBV “Hepatitis B Cure Symposium”
15/09/2025
– Oral presentation highlights significant reduction in HBV DNA integration and other clinically-relevant biomarkers from the EBT-107 therapeutic candidate in preclinical mouse models WATERTOWN, Mass., Sept. 15, 2025 ( [...]
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
15/09/2025
SPY072 is a potential first- and best-in-class anti-TL1A antibody for rheumatic diseases targeting quarterly or twice-yearly subcutaneous dosing SKYWAY study is evaluating SPY072 in patients with moderate-to-severely [...]
ABLi Therapeutics to Present “Clinical Breakthrough Lecture” at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
15/09/2025
ATLANTA and BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl [...]
Extendicare Announces September 2025 Dividend of C$0.042 per Share
15/09/2025
MARKHAM, Ontario, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month [...]
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
15/09/2025
Company to share new independent research on TTP-RA, vTv’s oral RAGE antagonist HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today [...]
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
15/09/2025
Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics across the spectrum [...]
Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025
15/09/2025
CAMBRIDGE, Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary [...]
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
15/09/2025
BOCA RATON, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or “the Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the [...]
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
15/09/2025
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment [...]
Picard Medical Reports Second Quarter 2025 Financial Results
15/09/2025
Strong commercial momentum driven by higher product sales – Total revenue and $19.5 million IPO proceeds support expansion and innovation in artificial heart technology - TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE [...]
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
15/09/2025
Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) [...]
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
15/09/2025
Oral semaglutide (Rybelsus ® ) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits 1 This approval is based on results from the SOUL clinical trial, where oral [...]
Request for Secretary of State of Texas, Jane Nelson, to Organize a Public Meeting Between Crosetto and CPRIT Scientists Who Have Allocated $3.65 Billion of $6 Billion to Cancer Research
15/09/2025
Support Transparency in the Use of $6 Billion for Cancer Research in Texas DALLAS, Sept. 15, 2025 (GLOBE NEWSWIRE) -- (In PDF https://bit.ly/ 3VPIFvY ) The Crosetto Foundation for the Reduction of Cancer Deaths , a [...]
KFSHRC Reduces Emergency Department Inpatient Bed Waiting Time by 75%
15/09/2025
RIYADH, Saudi Arabia, Sept. 15, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has reduced the median emergency department boarding time from over 13 hours in 2023 to [...]
Sienna Announces September Dividend
15/09/2025
MARKHAM, Ontario, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease
15/09/2025
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025 SYDNEY, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Actinogen [...]
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
15/09/2025
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development [...]

Pages